Case-control cohort study of patients' perceptions of disability in mastocytosis.

<h4>Background</h4>Indolent forms of mastocytosis account for more than 90% of all cases, but the types and type and severity of symptoms and their impact on the quality of life have not been well studied. We therefore performed a case-control cohort study to examine self-reported disabi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Olivier Hermine, Olivier Lortholary, Phillip S Leventhal, Adeline Catteau, Frédérique Soppelsa, Cedric Baude, Annick Cohen-Akenine, Fabienne Palmérini, Katia Hanssens, Ying Yang, Hagay Sobol, Sylvie Fraytag, David Ghez, Felipe Suarez, Stéphane Barete, Philippe Casassus, Beatrice Sans, Michel Arock, Jean Pierre Kinet, Patrice Dubreuil, Alain Moussy
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2008
Materias:
R
Q
Acceso en línea:https://doaj.org/article/c7a9aa9cd18f44c892d09c46322acbf3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:c7a9aa9cd18f44c892d09c46322acbf3
record_format dspace
spelling oai:doaj.org-article:c7a9aa9cd18f44c892d09c46322acbf32021-11-25T06:12:18ZCase-control cohort study of patients' perceptions of disability in mastocytosis.1932-620310.1371/journal.pone.0002266https://doaj.org/article/c7a9aa9cd18f44c892d09c46322acbf32008-05-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18509466/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Indolent forms of mastocytosis account for more than 90% of all cases, but the types and type and severity of symptoms and their impact on the quality of life have not been well studied. We therefore performed a case-control cohort study to examine self-reported disability and impact of symptoms on the quality of life in patients with mastocytosis.<h4>Methodology/principal findings</h4>In 2004, 363 mastocytosis patients and 90 controls in France were asked to rate to their overall disability (OPA score) and the severity of 38 individual symptoms. The latter was used to calculate a composite score (AFIRMM score). Of the 363 respondents, 262 were part of an ongoing pathophysiological study so that the following data were available: World Health Organization classification, standard measures of physical and psychological disability, existence of the D816V KIT mutation, and serum tryptase level. The mean OPA and AFIRMM scores and the standard measures of disability indicated that most mastocytosis patients suffer from disabilities due to the disease. Surprisingly, the patient's measurable and perceived disabilities did not differ according to disease classification or presence or absence of the D816V KIT mutation or an elevated (> or = 20 ng/mL) serum tryptase level. Also, 32 of the 38 AFIRMM symptoms were more common in patients than controls, but there were not substantial differences according to disease classification, presence of the D816V mutation, or the serum tryptase level.<h4>Conclusions</h4>On the basis of these results and for the purposes of treatment, we propose that mastocytosis be first classified as aggressive or indolent and that indolent mastocytosis then be categorized according to the severity of patients' perceived symptoms and their impact on the quality of life. In addition, it appears that mastocytosis patients suffer from more symptoms and greater disability than previously thought, that mastocytosis may therefore be under-diagnosed, and that the symptoms of the indolent forms of mastocytosis might be due more to systemic release of mediators than mast cell burden.Olivier HermineOlivier LortholaryPhillip S LeventhalAdeline CatteauFrédérique SoppelsaCedric BaudeAnnick Cohen-AkenineFabienne PalmériniKatia HanssensYing YangHagay SobolSylvie FraytagDavid GhezFelipe SuarezStéphane BaretePhilippe CasassusBeatrice SansMichel ArockJean Pierre KinetPatrice DubreuilAlain MoussyPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 3, Iss 5, p e2266 (2008)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Olivier Hermine
Olivier Lortholary
Phillip S Leventhal
Adeline Catteau
Frédérique Soppelsa
Cedric Baude
Annick Cohen-Akenine
Fabienne Palmérini
Katia Hanssens
Ying Yang
Hagay Sobol
Sylvie Fraytag
David Ghez
Felipe Suarez
Stéphane Barete
Philippe Casassus
Beatrice Sans
Michel Arock
Jean Pierre Kinet
Patrice Dubreuil
Alain Moussy
Case-control cohort study of patients' perceptions of disability in mastocytosis.
description <h4>Background</h4>Indolent forms of mastocytosis account for more than 90% of all cases, but the types and type and severity of symptoms and their impact on the quality of life have not been well studied. We therefore performed a case-control cohort study to examine self-reported disability and impact of symptoms on the quality of life in patients with mastocytosis.<h4>Methodology/principal findings</h4>In 2004, 363 mastocytosis patients and 90 controls in France were asked to rate to their overall disability (OPA score) and the severity of 38 individual symptoms. The latter was used to calculate a composite score (AFIRMM score). Of the 363 respondents, 262 were part of an ongoing pathophysiological study so that the following data were available: World Health Organization classification, standard measures of physical and psychological disability, existence of the D816V KIT mutation, and serum tryptase level. The mean OPA and AFIRMM scores and the standard measures of disability indicated that most mastocytosis patients suffer from disabilities due to the disease. Surprisingly, the patient's measurable and perceived disabilities did not differ according to disease classification or presence or absence of the D816V KIT mutation or an elevated (> or = 20 ng/mL) serum tryptase level. Also, 32 of the 38 AFIRMM symptoms were more common in patients than controls, but there were not substantial differences according to disease classification, presence of the D816V mutation, or the serum tryptase level.<h4>Conclusions</h4>On the basis of these results and for the purposes of treatment, we propose that mastocytosis be first classified as aggressive or indolent and that indolent mastocytosis then be categorized according to the severity of patients' perceived symptoms and their impact on the quality of life. In addition, it appears that mastocytosis patients suffer from more symptoms and greater disability than previously thought, that mastocytosis may therefore be under-diagnosed, and that the symptoms of the indolent forms of mastocytosis might be due more to systemic release of mediators than mast cell burden.
format article
author Olivier Hermine
Olivier Lortholary
Phillip S Leventhal
Adeline Catteau
Frédérique Soppelsa
Cedric Baude
Annick Cohen-Akenine
Fabienne Palmérini
Katia Hanssens
Ying Yang
Hagay Sobol
Sylvie Fraytag
David Ghez
Felipe Suarez
Stéphane Barete
Philippe Casassus
Beatrice Sans
Michel Arock
Jean Pierre Kinet
Patrice Dubreuil
Alain Moussy
author_facet Olivier Hermine
Olivier Lortholary
Phillip S Leventhal
Adeline Catteau
Frédérique Soppelsa
Cedric Baude
Annick Cohen-Akenine
Fabienne Palmérini
Katia Hanssens
Ying Yang
Hagay Sobol
Sylvie Fraytag
David Ghez
Felipe Suarez
Stéphane Barete
Philippe Casassus
Beatrice Sans
Michel Arock
Jean Pierre Kinet
Patrice Dubreuil
Alain Moussy
author_sort Olivier Hermine
title Case-control cohort study of patients' perceptions of disability in mastocytosis.
title_short Case-control cohort study of patients' perceptions of disability in mastocytosis.
title_full Case-control cohort study of patients' perceptions of disability in mastocytosis.
title_fullStr Case-control cohort study of patients' perceptions of disability in mastocytosis.
title_full_unstemmed Case-control cohort study of patients' perceptions of disability in mastocytosis.
title_sort case-control cohort study of patients' perceptions of disability in mastocytosis.
publisher Public Library of Science (PLoS)
publishDate 2008
url https://doaj.org/article/c7a9aa9cd18f44c892d09c46322acbf3
work_keys_str_mv AT olivierhermine casecontrolcohortstudyofpatientsperceptionsofdisabilityinmastocytosis
AT olivierlortholary casecontrolcohortstudyofpatientsperceptionsofdisabilityinmastocytosis
AT phillipsleventhal casecontrolcohortstudyofpatientsperceptionsofdisabilityinmastocytosis
AT adelinecatteau casecontrolcohortstudyofpatientsperceptionsofdisabilityinmastocytosis
AT frederiquesoppelsa casecontrolcohortstudyofpatientsperceptionsofdisabilityinmastocytosis
AT cedricbaude casecontrolcohortstudyofpatientsperceptionsofdisabilityinmastocytosis
AT annickcohenakenine casecontrolcohortstudyofpatientsperceptionsofdisabilityinmastocytosis
AT fabiennepalmerini casecontrolcohortstudyofpatientsperceptionsofdisabilityinmastocytosis
AT katiahanssens casecontrolcohortstudyofpatientsperceptionsofdisabilityinmastocytosis
AT yingyang casecontrolcohortstudyofpatientsperceptionsofdisabilityinmastocytosis
AT hagaysobol casecontrolcohortstudyofpatientsperceptionsofdisabilityinmastocytosis
AT sylviefraytag casecontrolcohortstudyofpatientsperceptionsofdisabilityinmastocytosis
AT davidghez casecontrolcohortstudyofpatientsperceptionsofdisabilityinmastocytosis
AT felipesuarez casecontrolcohortstudyofpatientsperceptionsofdisabilityinmastocytosis
AT stephanebarete casecontrolcohortstudyofpatientsperceptionsofdisabilityinmastocytosis
AT philippecasassus casecontrolcohortstudyofpatientsperceptionsofdisabilityinmastocytosis
AT beatricesans casecontrolcohortstudyofpatientsperceptionsofdisabilityinmastocytosis
AT michelarock casecontrolcohortstudyofpatientsperceptionsofdisabilityinmastocytosis
AT jeanpierrekinet casecontrolcohortstudyofpatientsperceptionsofdisabilityinmastocytosis
AT patricedubreuil casecontrolcohortstudyofpatientsperceptionsofdisabilityinmastocytosis
AT alainmoussy casecontrolcohortstudyofpatientsperceptionsofdisabilityinmastocytosis
_version_ 1718414069366521856